关于上海交大昂立股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：上海交大昂立股份有限公司 审计单位：山东舜天信诚会计师事务所(特殊普通合伙) 联系电话：（021）5427-1688 上海交大昂立股份有限公司 控股股东及其他关联方资金占用情况的 审核报告 舜天信诚证专审字(2024)第 003 号 山 东 舜 天 信 诚 会 计 师 事 务 所(特 殊 普 通 合 伙) SHTXC Certified Public Accountants (Special General Partnership) 您可使用手机"扫一扫"成进入"注册会计师行业统一监管平台（bttp://www.mof.gov.cn）" 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（bttp://788.com/.gov.cn）"20.080.158 上海交大昂立股份有限公司 控股股东及其他关联方资金占用情况的审核报告 (截止 2023 年 12 月 31 日) | | | 控 股 股 东 及 其 他 关 联 方 资 金 占 用 情 况 的 审 核 报 告 ...

证券代码：600530 证券简称：ST 交昂 公告编号：临 2024-011 上海交大昂立股份有限公司 关于2023年度拟不进行利润分配的公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 根据中国证券监督管理委员会（以下简称证监会）发布的《上市公司监管指引第 3 号——上市公司现金分红》等法律、法规、规范性文件及《公司章程》等相关规定，基 于 2023 年度净利润为负值，未实现盈利，经综合考虑，结合公司当前经营情况、未来 发展规划和资金需求等因素，为保障公司正常生产经营，实现持续、稳定、健康发展， 更好地维护全体股东的长远利益，公司 2023 年度拟不进行利润分配，资本公积金不转 增股本。 公司留存未分配利润将主要用于满足公司日常经营需要，支持公司各项业务的开展 以及流动资金需求等，为公司中长期发展战略的顺利实施以及持续、健康发展提供可靠 的保障。公司将始终严格按照相关法律法规和《公司章程》等规定，从有利于公司发展 和投资者回报的角度出发，积极履行公司的利润分配制度，与投资者共享公司发展的成 果。 三、公司 ...

上海交大昂立股份有限公司 2023 年度独立董事述职报告 萧耀熙 作为上海交大昂立股份有限公司 (以下简称"公司")的独立董事，本人在2023年 度工作中，严格按照《公司法》《上海证券交易所股票上市规则》《上海证券交易所 上市公司自律监管指引第1号——规范运作》《上市公司独立董事管理办法》等法律、 法规和规范性文件，以及《公司章程》《独立董事工作制度》等公司规章和制度，凭 借丰富的专业知识和经验，积极参加公司董事会及各专门委员会会议、股东大会，在 董事会日常工作及决策中尽职尽责，对董事会审议的重大事项发表了独立客观的意 见，为董事会的科学决策提供支撑，促进公司规范运作，本着对全体股东负责的态 度，忠实、勤勉履行独立董事职责。现将本人于2023年度工作情况作如下报告： 一、独立董事的基本情况 （一）个人工作履历、专业背景及兼职情况 作为公司的独立董事，本人拥有专业资质及能力，在从事的专业领域积累了丰富 的经验。本人个人工作履历、专业背景以及兼职情况如下： 本人萧耀熙，男，加拿大滑铁卢大学数学学士，香港注册会计师，加拿大安省特 许专业会计师。本人具备丰富的会计专业知识和经验，自1996年6月至2023年5月，在 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥75,550,297.09, representing a decrease of 17.28% compared to the same period last year[4]. - The net profit attributable to shareholders was -¥3,319,302.29, a decline of 328.40% year-over-year[4]. - The net cash flow from operating activities was -¥22,718,736.39, reflecting a decrease of 321.86% compared to the previous year[4]. - Basic earnings per share were -¥0.004, down 314.17% from the same quarter last year[4]. - The company reported a net loss of CNY 679,673,041.71 for Q1 2024, compared to a net loss of CNY 676,353,739.42 in Q1 2023[13]. - In Q1 2024, the company reported a net profit of -2,167,529.60 yuan, a significant decline compared to a net profit of 3,379,802.30 yuan in Q1 2023[17]. - The company recorded a total revenue from sales of goods and services of 79,332,571.77 yuan in Q1 2024, down from 96,496,714.59 yuan in Q1 2023, indicating a decline of about 17.8%[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥780,613,881.84, a decrease of 4.23% from the end of the previous year[4]. - Total assets decreased to CNY 780,613,881.84 as of March 31, 2024, from CNY 815,095,058.94 at the end of 2023, a reduction of 4.2%[13]. - Total liabilities decreased to CNY 443,602,139.67 as of March 31, 2024, from CNY 475,915,787.16 at the end of 2023, a decline of 6.8%[13]. - Current liabilities totaled CNY 275,095,479.87 as of March 31, 2024, down from CNY 302,137,762.57 at the end of 2023, a decrease of 9.0%[12]. - Non-current assets increased to CNY 565,721,447.65 as of March 31, 2024, compared to CNY 543,343,771.44 at the end of 2023, an increase of 4.1%[12]. Shareholder Information - The company had a total of 19,911 common shareholders at the end of the reporting period[8]. - The largest shareholder, Dazhong Transportation Group Co., Ltd., held 14.48% of the shares[8]. - There are no significant changes in the top 10 shareholders or their shareholding status compared to the previous period[9]. Cash Flow and Expenses - Cash and cash equivalents as of March 31, 2024, were CNY 106,013,334.71, down from CNY 164,096,632.69 at the end of 2023, representing a decline of 35.3%[11]. - The company's cash flow from operating activities showed a net outflow of -22,718,736.39 yuan in Q1 2024, compared to a net inflow of 10,240,053.62 yuan in Q1 2023[21]. - Cash and cash equivalents at the end of Q1 2024 were 106,013,334.71 yuan, down from 135,781,873.43 yuan at the end of Q1 2023, reflecting a decrease of approximately 22%[22]. - The company incurred a total of 54,204,624.01 yuan in cash outflows from financing activities in Q1 2024, slightly lower than 54,609,344.31 yuan in Q1 2023[22]. - The company reported an investment activity cash flow net outflow of -1,317,820.51 yuan in Q1 2024, compared to -5,014,737.81 yuan in Q1 2023, showing an improvement in investment cash flow[21]. Operational Challenges - The decline in net profit was primarily due to decreased revenue in the health products segment and increased management expenses[6]. - The total operating costs decreased from 83,892,847.43 yuan in Q1 2023 to 76,561,612.96 yuan in Q1 2024, representing a reduction of approximately 8.5%[17]. - Research and development expenses dropped from 3,094,219.57 yuan in Q1 2023 to 965,476.30 yuan in Q1 2024, a decrease of about 68.8%[17]. - The company experienced a credit impairment loss of 80,416.26 yuan in Q1 2024, a significant recovery from a loss of -9,201,094.41 yuan in Q1 2023[17]. - The company has not reported any new product launches or significant technological advancements during this quarter[10].

Financial Performance - The company reported a consolidated net profit attributable to the parent company of -35,084,389.73 yuan for the year 2023, with cumulative undistributed profits amounting to -676,353,739.42 yuan[7]. - The parent company achieved a net profit of -20,140,248.20 yuan for 2023, with no surplus reserve provision made, resulting in cumulative undistributed profits of 159,458,726.51 yuan[7]. - The company plans not to distribute profits for 2023 and will not convert capital reserves into share capital due to the overall loss for the year[7]. - The company's operating revenue for 2023 was approximately ¥296.33 million, a decrease of 21.43% compared to ¥377.15 million in 2022[24]. - The net profit attributable to shareholders was a loss of approximately ¥35.08 million, improving by 92.96% from a loss of ¥498.62 million in 2022[24]. - The basic earnings per share for 2023 was -¥0.05, a significant improvement of 92.92% from -¥0.64 in 2022[26]. - The weighted average return on equity increased by 74.93 percentage points to -11.23% in 2023 from -86.16% in 2022[26]. - The company reported a net cash flow from operating activities of approximately ¥55.54 million, down 43.49% from ¥98.27 million in 2022[24]. - The total assets decreased by 7.97% to approximately ¥815.10 million at the end of 2023, down from ¥885.67 million at the end of 2022[24]. - The company achieved total revenue of CNY 296.33 million in 2023, a decrease of 21.43% compared to CNY 377.15 million in the previous year[60]. - The company's operating costs were CNY 229.72 million, slightly down by 0.43% from CNY 230.72 million in the previous year[60]. - Sales expenses decreased by 23.53% to CNY 29.94 million, while management expenses increased by 15.71% to CNY 42.06 million[60]. - Research and development expenses were reduced by 49.45% to CNY 5.92 million, indicating a shift in focus[60]. - The company reported a total sales expense of CNY 2,993.51, with employee compensation making up 56.31% of this total[98]. Audit and Compliance - The audit report issued by Shandong Shuntian Xincheng Accounting Firm includes a qualified opinion, which the company acknowledges and has provided detailed explanations for[6]. - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties[9]. - There are no violations of decision-making procedures regarding external guarantees[10]. - The company has not faced a situation where more than half of the directors cannot guarantee the authenticity, accuracy, and completeness of the annual report[10]. - The company emphasizes the importance of investor awareness regarding the risks associated with forward-looking statements in the report[8]. - The company received a qualified audit opinion from Shandong Shuntian Xincheng Accounting Firm regarding its 2023 financial statements, primarily due to insufficient audit evidence related to asset impairment losses totaling RMB 58.1 million[194][197]. - The company confirmed that the qualified audit opinion does not affect its financial condition, operating results, or cash flow for the reporting period[198]. - The company has not disclosed a separate social responsibility report, sustainability report, or ESG report for the reporting period[189]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[192]. - The company's financial statements fairly reflect its consolidated and parent company financial position as of December 31, 2023, in accordance with accounting standards[200]. Market and Product Development - The company focused on optimizing its sales channels and enhancing service quality in the health product sector, closing high-cost, low-sales offline channels[36]. - The flagship product, Angli Duobang capsules, has sold nearly 4 billion units, with over 10 million users, highlighting its strong market presence[36]. - The company is actively promoting new products in the probiotic category, including Angli No. 1 probiotic granules and Angli Super Probiotics[36]. - The company aims to streamline its product line and pricing system to enhance overall brand image and profitability while reducing operational costs[36]. - The company has successfully completed the expansion project for probiotic powder production at the Songjiang plant in 2023, enhancing production efficiency to meet supply demands[37]. - In 2023, the company obtained an international patent in Malaysia for a composition promoting glucolipid metabolism, reflecting its strong R&D capabilities[38]. - The health food industry in China is projected to exceed RMB 800 billion by 2027, with a significant trend towards younger consumers driving growth[42]. - The overall scale of China's health industry reached approximately RMB 13.5 trillion in 2023, marking a 6.3% increase from 2022, with a forecasted growth rate of 5%-7% in the coming years[43]. - The company has developed several new products, including the Angli Duobang compound candy and Angli Super Original probiotic powder, aligning with market trends[38]. - The company is actively expanding its international sales channels, maintaining growth in the US and European markets while exploring opportunities in Australia, New Zealand, and Southeast Asia[37]. Governance and Management - The company has established a performance evaluation system linking executive compensation to business performance, ensuring transparency in senior management appointments[120]. - The company held 1 annual and 5 temporary shareholder meetings during the reporting period, ensuring equal rights for all shareholders[115]. - The company disclosed 4 periodic reports and 138 announcements in 2023, maintaining accurate and timely information disclosure[122]. - The company is committed to enhancing investor relations through multiple communication channels, including investor meetings and dedicated sections on its website[121]. - The company has implemented strict insider information management practices to protect investor rights and ensure fair information disclosure[123]. - The company has established a complete independent legal asset system, with full control over all assets, ensuring no asset or funds are occupied by the controlling shareholder[126]. - The company has an independent human resources management department, ensuring personnel and salary management is separate from the controlling shareholder[126]. - The company operates an independent financial accounting department with a standardized financial management system, ensuring independent financial decision-making[126]. - The company has a well-established organizational structure that operates independently and effectively, with no subordinate relationship to the controlling shareholder[126]. - The company has revised its articles of association and various governance rules to enhance operational standards and promote high-quality development[124]. - The company has conducted comprehensive self-inspections on corporate governance and internal control, continuously improving its governance level[124]. - The company has not encountered significant differences in governance regulations compared to the requirements set by the China Securities Regulatory Commission[124]. - The company has no significant competition issues with its controlling shareholder or related parties[127]. Environmental and Social Responsibility - The company invested 517,700 CNY in environmental protection during the reporting period[185]. - The company has engaged a qualified third-party testing agency to conduct regular monitoring of pollutant emissions, ensuring compliance with environmental standards[186]. - The company has conducted emergency training and drills for environmental incidents to improve employee response capabilities[187]. - The company donated RMB 1 million (approximately $100,000) to the China Charity Federation for emergency relief and disaster reconstruction in Gansu and Qinghai provinces following significant earthquakes[189]. - The company reported a total investment of RMB 1 million in social responsibility initiatives during the reporting period[189]. Legal and Regulatory Challenges - The company received a warning and a fine of CNY 500,000 due to failure to disclose the 2022 annual report by the legal deadline of April 30, 2023[148]. - The company has been penalized for regulatory non-compliance, with fines imposed on key executives including the former chairman and acting board secretary[148]. - The company is currently reviewing its governance practices in light of the ongoing legal and regulatory challenges[155]. - The board has expressed concerns regarding the appropriateness of appointing Zhu Yingzheng as president due to his lack of relevant experience in the health industry[154]. - The company is facing potential claims exceeding 20 million related to allegations of asset misappropriation involving insurance transactions[155]. - The company has identified significant accounting errors that have delayed the disclosure of the annual report, attributed to the lack of professional auditing capabilities of the current auditing firm[155]. - The internal control evaluation report has not fully reflected the company's multiple violations from the previous year[155]. - The company is advised to consider alternative auditing firms due to the current auditor's deficiencies in professional auditing capabilities[155]. - The board has indicated that any proposals lacking legal basis and factual support will not be submitted for shareholder vote[155].

上海交大昂立股份有限公司 2023 年度独立董事述职报告 王涛 作为上海交大昂立股份有限公司 (以下简称"公司")的独立董事，本人在2023年 度工作中，严格按照《公司法》《上海证券交易所股票上市规则》《上海证券交易所 上市公司自律监管指引第1号——规范运作》《上市公司独立董事管理办法》等法律、 法规和规范性文件，以及《公司章程》《独立董事工作制度》等公司规章和制度，凭 借丰富的专业知识和经验，积极参加公司董事会及各专门委员会会议、股东大会，在 董事会日常工作及决策中尽职尽责，对董事会审议的重大事项发表了独立客观的意 见，为董事会的科学决策提供支撑，促进公司规范运作，本着对全体股东负责的态 度，忠实、勤勉履行独立董事职责。现将本人于2023年度工作情况作如下报告： 一、独立董事的基本情况 （一）个人工作履历、专业背景及兼职情况 作为公司的独立董事，本人拥有专业资质及能力，在从事的专业领域积累了丰富 的经验。本人个人工作履历、专业背景以及兼职情况如下： 本人王涛，男，1969年出生，南京大学计算机软件学士、西南德州大学计算机软 件硕士。本人曾先后在微软、创维、金山、阿里巴巴等企业担任高管，在IT、互联 网、科技 ...

证券代码：600530 证券简称：ST 交昂 公告编号：临 2024-009 上海交大昂立股份有限公司 第八届董事会第三十三次会议决议公告 上海交大昂立股份有限公司（以下简称"公司"）第八届董事会第三十三次会议的 召开符合《公司法》和《公司章程》的有关规定。本次会议通知和材料于 2024 年 4 月 15 日以微信群方式向全体董事发出，会议于 2024 年 4 月 25 日下午以现场会议与腾讯 视频相结合的方式召开。 出席会议的董事应到 7 名，现场出席会议的董事 4 名，视频出席会议的董事 3 名。 会议由董事长嵇敏先生主持。公司监事、高级管理人员列席会议。 二、董事会会议审议情况 （一）审议通过《公司 2023 年度董事会工作报告》 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《公司 2023 年度董事会工作报告》。 本议案尚需提交 2023 年年度股东大会进行审议。 同意 7 票，反对 0 票，弃权 0 票，审议通过。 （二）审议通过《公司 2023 年度总裁工作报告》 同意 7 票，反对 0 票，弃权 0 票，审议通过。 本公司董事会及全体董事保证公告内容不存在虚假记 ...

公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制评价结果推测未来内部控制的有效性具有一定的风险。 二. 内部控制评价结论 1. 公司于内部控制评价报告基准日，是否存在财务报告内部控制重大缺陷 □是 √否 公司代码：600530 公司简称：ST 交昂 上海交大昂立股份有限公司 2023 年度内部控制评价报告 上海交大昂立股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实 ...

上海交大昂立股份有限公司 董事会审计委员会 2023 年度履职报告 根据《上市公司治理准则》、上海证券交易所《股票上市规则》以及《公司章程》《董 事会审计委员会工作条例》等有关规定，公司董事会审计委员会恪尽职守、积极有效地 履行了审计委员会的职责。现就 2023 年度审计委员会履职情况报告如下: 一、审计委员会基本情况 （一）2023 年末审计委员会委员情况 截止 2023 年末，公司第八届董事会审计委员会由独立董事萧耀熙先生、王涛先生、 宋振华先生以及非独立董事嵇敏先生、何俊先生 5 名董事组成，其中主任委员由具有会 计专业资格的独立董事萧耀熙先生担任。 （二）审计委员会委员变更情况 2023 年 9 月 26 日、11 月 20 日，公司分别召开第八届董事会第二十六次会议及 2022 年年度股东大会，审议通过了《关于增补独立董事的议案》，增补萧耀熙先生为公司第八 届董事会独立董事，任期至公司第八届董事会届满之日止。 根据《上海证券交易所股票上市规则》（2023 年 8 月修订）第 4.2.12 条规定，审计 委员会成员应当为不在上市公司担任高级管理人员的董事。2023 年 11 月 22 日，公司财 务总 ...

上海交大昂立股份有限公司 关于修订《公司章程》的公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600530 证券简称：ST 交昂 公告编号：临 2024-014 根据《上市公司章程指引（2023 年修订）》《上市公司监管指引第 3 号——上市公 司现金分红（2023 年修订）》等相关规定，结合上海交大昂立股份有限公司（以下简称 "公司"）治理实际需要，公司于 2024 年 4 月 25 日召开第八届董事会第三十三次会 议，审议通过了《关于修订<公司章程>的议案》，拟对《公司章程》中涉及的部分条款进 行修订，具体修订内容如下： | 修订前 | 修订后 | | --- | --- | | 第一百五十五条 公司股东大会对利润分配 | 第一百五十五条公司股东大会对利润分配方案作 | | 方案作出决议后，公司董事会须在股东大会召开 | 出决议后，或公司董事会根据年度股东大会审议通过 | | 后 2 个月内完成股利（或股份）的派发事项。 | 的下一年中期分红条件和上限制定具体方案后，须在 | | | 两个月内完成股利（或 ...